Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | ELANE | P08246 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19532862 | 0.87 | NPC1 (0.34) | MEN1KMT2AALDH1A1NPC1RAB9A | |
| SCHEMBL20786103 | 0.87 | NPC1 (0.35) | MEN1KMT2AALDH1A1NPC1RAB9A | |
| SCHEMBL29471925 | 0.86 | NPC1 (0.40) | MEN1KMT2AGAAALDH1A1NPC1 | |
| SCHEMBL2248688 | 0.86 | NPC1 (0.40) | MEN1KMT2AGAAALDH1A1NPC1 | |
| SCHEMBL29388571 | 0.86 | NPC1 (0.40) | MEN1KMT2AGAAALDH1A1NPC1 | |
| SCHEMBL19222240 | 0.86 | ALOX15 (0.39) | MEN1KMT2AALDH1A1NPC1RAB9A | |
| SCHEMBL21906781 | 0.85 | NPSR1 (0.33) | NPC1RAB9A | |
| SCHEMBL19603297 | 0.84 | ALDH1A1 (0.40) | MEN1KMT2AALDH1A1NPC1RAB9A | |
| SCHEMBL2250757 | 0.84 | ALDH1A1 (0.40) | MEN1KMT2AALDH1A1NPC1RAB9A | |
| SCHEMBL29790770 | 0.84 | ALDH1A1 (0.40) | MEN1KMT2AALDH1A1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9975872-B2 | Processes for the preparation of (s)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable forms thereof | CELGENE CORPORATION (US) | 2018-05-22 | — | — | US | disclosed |
| US-20170267658-A1 | PROCESSES FOR THE PREPARATION OF ISOTOPOLOGUES OF 3-(4-((4-(MORPHOLINOMETHYL)BENZYL)OXY)-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | CELGENE CORPORATION | 2017-09-21 | — | — | US | disclosed |
| US-9695145-B2 | Processes for the preparation of isotopologues of 3-(4-((4- morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable salts thereof | CELGENE CORPORATION (US) | 2017-07-04 | — | — | US | disclosed |
| US-20150361066-A1 | PROCESSES FOR THE PREPARATION OF ISOTOPOLOGUES OF 3-(4-((4-(MORPHOLINOMETHYL)BENZYL)OXY)-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | CELGENE CORPORATION | 2015-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150361066-A1 | PROCESSES FOR THE PREPARATION OF ISOTOPOLOGUES OF 3-(4-((4-(MORPHOLINOMETHYL)BENZYL)OXY)-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | DHPS, DAD1, AQP1 | MEN1 2429/4885KMT2A 4183/4885GAA 1309/4885 |
| US-20170267658-A1 | PROCESSES FOR THE PREPARATION OF ISOTOPOLOGUES OF 3-(4-((4-(MORPHOLINOMETHYL)BENZYL)OXY)-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | DHPS, AQP4, AQP1 | MEN1 2444/4885KMT2A 2914/4885GAA 1576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.